Extracorporeal virus elimination for the treatment of severe ebola virus disease - First experience with lectin affinity plasmapheresis

Blood Purification

Volumn 38, Issue 3-4, 2014, Pages 286-291

  Büttner, Stefan ^a   Koch, Benjamin ^a   Dolnik, Olga ^b   Eickmann, Markus ^b   Freiwald, Tilo ^a   Rudolf, Sarah ^a   Engel, Jürgen ^a   Becker, Stephan ^b   Ronco, Claudio ^c   Geiger, Helmut ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Ebola virus; Glycoprotein; Lectin affinity; Plasmapheresis

Indexed keywords

GLYCOPROTEIN; LECTIN; ANTICOAGULANT AGENT; CITRIC ACID; MANNOSE; MANNOSE BINDING LECTIN; PLANT LECTIN; SNOWDROP LECTIN; VIRUS ENVELOPE PROTEIN;

ARTICLE; DISEASE SEVERITY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ELUTION; EXTRACORPOREAL CIRCULATION; HUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS LOAD; ADULT; ARTIFICIAL KIDNEY; CASE REPORT; CHEMISTRY; HEMORRHAGIC FEVER, EBOLA; INTENSIVE CARE; ISOLATION AND PURIFICATION; MALE; MULTIMODALITY CANCER THERAPY; PROCEDURES; RENAL REPLACEMENT THERAPY; UGANDA; VIREMIA;

ADULT; ANTICOAGULANTS; CITRATES; COMBINED MODALITY THERAPY; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; INTENSIVE CARE; KIDNEYS, ARTIFICIAL; MALE; MANNOSE; MANNOSE-BINDING LECTINS; PLANT LECTINS; PLASMAPHERESIS; RENAL DIALYSIS; UGANDA; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIREMIA;

EID: 84929656244     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000375229     Document Type: Article

References (28)

1. WHO. Ebola Response Roadmap Situation Report, 31 December 2014. http://www.who. int/csr/disease/ebola/situation-reports/en/.
2. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RS, Kanneh L, Moigboi A, Momoh M, Fullah M, Moses LM, Brown BL, Andersen KG, Winnicki S, Schaffner SF, Park DJ, Yozwiak NL, Jiang PP, Kargbo D, Jalloh S, Fonnie M, Sinnah V, French I, Kovoma A, Kamara FK, Tucker V, Konuwa E, Sellu J, Mustapha I, Foday M, Yillah M, Kanneh F, Saffa S, Massally JL, Boisen ML, Branco LM, Vandi MA, Grant DS, Happi C, Gevao SM, Fletcher TE, Fowler RA, Bausch DG, Sabeti PC, Khan SH, Garry RF. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014; 371: 2092-2100.
3. Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 2007; 7: 556-567.
4. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog 2010; 6:e1001098.
5. Cook JD, Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog 2013; 9:e1003258.
6. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010; 4:pii:e837.
7. Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun 2014; 55C:1-9.
8. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog 2014; 10:e100459.
9. Lamontagne F, Clement C, Fletcher T, Jacob ST, Fischer WA 2nd, Fowler RA. Doing today's work superbly well-Treating Ebola with current tools. N Engl J Med 2014; 371: 1565-1566.
10. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, Sow A, Renne T, Gunther S, Lohse AW, Addo MM, Schmiedel S. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 371: 2394-2401.
11. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, Shindo N, Fischer WA 2nd, Lamontagne F, Saliou SM, Bausch DG, Moumie B, Jagatic T, Sprecher A, Lawler JV, Mayet T, Jacquerioz FA, Mendez Baggi MF, Vallenas C, Clement C, Mardel S, Faye O, Faye O, Soropogui B, Magassouba N, Koivogui L, Pinto R, Fowler RA. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2015; 372: 40-47.
12. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, de Leuw P, Grunewald T, Vogl T, Kempf VA, Keppler OT, Zacharowski K. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 2014;pii:S0140-6736(14) 62384-9.
13. Tullis RH, Duffin RP, Handley HH, Sodhi P, Menon J, Joyce JA, Kher V. Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients. Blood Purif 2009; 27: 64-69.
14. Lupien PJ, Moorjani S, Awad J. A new approach to the management of familial hypercholesterolaemia: removal of plasmacholesterol based on the principle of affinity chromatography. Lancet 1976; 1: 1261-1265.
15. Cosset FL, Lavillette D. Cell entry of enveloped viruses. Adv Genet 2011; 73: 121-183.
16. Mahmood N, Hay AJ. An ELISA utilizing immobilised snowdrop lectin GNA for the detection of envelope glycoproteins of HIV and SIV. J Immunol Methods 1992; 151: 9-13.
17. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, Spiropoulou C, Stroher U, Uyeki TM, Ribner BS. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; 371: 2402-2409.
18. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa-clinical manifestations and management. N Engl J Med 2014; 371: 2054-2057.
19. Connor MJ Jr, Kraft C, Mehta AK, Varkey JB, Lyon GM, Crozier I, Stroher U, Ribner BS, Franch HA. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol 2015; 26: 31-37.
20. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375: 1896-1905.
21. Yazdanpanah Y, Arribas JR, Malvy D. Treatment of Ebola virus disease. Intensive Care Med 2015; 41: 115-117.
22. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pohlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014; 69: 2123-2131.
23. Groger M, Pasteiner W, Ignatyev G, Matt U, Knapp S, Atrasheuskaya A, Bukin E, Friedl P, Zinkl D, Hofer-Warbinek R, Zacharowski K, Petzelbauer P, Reingruber S. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One 2009; 4:e5391.
24. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514: 47-53.
25. Gulland A. Clinical trials of Ebola therapies to begin in December. BMJ 2014; 349:g6827.
26. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011; 204(suppl 3):S1075-S1081.
27. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis 2014; 210: 558-566.
28. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, Lee WF, Spiropoulou CF, Ksiazek TG, Lukwiya M, Kaducu F, Downing R, Nichol ST. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004; 78: 4330-4341.